Vaginal suppositories containing Lactobacillus acidophilus: development and characterization

References

• FAO/WHO. Evaluation of health and nutritional properties of probiotics in food, including powder milk with live lactic acid bacteria. FAO/WHO Expert Consultation Report 2001:1–34
   Google Scholar
• Naber KG. Treatment options for acute uncomplicated cystitis in adults. Antimicrob Agents Chemother 2000;46:23–7
   Web of Science ®Google Scholar
• Salminen S, von Wright A, Morelli L, et al. Demonstration of safety of probiotics – a review. Int J Food 1998;44:93–106
   PubMed Web of Science ®Google Scholar
• Boris S, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000;2:543–6
   PubMed Web of Science ®Google Scholar
• Reid G, Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 2002;4:319–24
   PubMed Web of Science ®Google Scholar
• Stöber H, Maier E, Schmidt H. Protective effects of lactobacilli, bifidobacteria and staphylococci on the infection of cultured HT29 cells with different enterohemorrhagic escherichia coli serotypes are strain-specific. Int J Food 2010;144:133–40
   PubMed Web of Science ®Google Scholar
• Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol R 2008;72:728–64
   PubMed Web of Science ®Google Scholar
• McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B 2011;86:58–64
   PubMed Web of Science ®Google Scholar
• Uehara S, Monden K, Nomoto K, et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006;28:30–4
   PubMed Web of Science ®Google Scholar
• Jones ML, Martoni CJ, Di Pietro E, et al. Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul Toxicol Pharm 2012;63:313–20
   PubMed Web of Science ®Google Scholar
• Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. Fems Immunol Med Mic 2003;35:131–4
   PubMed Web of Science ®Google Scholar
• Kaewnopparat S, Dangmanee N, Kaewnopparat N, et al. In vitro probiotic properties of Lactobacillus fermentum SK5 isolated from vagina of a healthy woman. Anaerobe 2013;22:6–13
   PubMed Web of Science ®Google Scholar
• Sobel JD. Bacterial vaginosis. Annu Rev Med 2000;51:349–56
   PubMed Web of Science ®Google Scholar
• Fuller R. Probiotics in man and animals. J Appl Microbiol 1989;66:365–78
   Web of Science ®Google Scholar
• FAO/WHO. Guidelines for the evaluation of probiotics in food. London, Ontario, Canada: FAO/WHO; 2002
   Google Scholar
• Reid G. Potential preventive strategies and therapies in urinary tract infection. World J Urol 1999;17:359–63
   PubMed Web of Science ®Google Scholar
• Iannitti T, Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 2010;29:701–25
   PubMed Web of Science ®Google Scholar
• Anukam KC, Osazuwa E, Osemene GI, et al. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 2006;8:2772–6
   PubMed Web of Science ®Google Scholar
• Ehrström S, Daroczy K, Rylander E, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 2010;12:691–9
   PubMed Web of Science ®Google Scholar
• Vujic G, Jajac Knez A, Despot Stefanovic V, Kuzmic Vrbanovic V. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study. Eur J Obstet Gyn R B 2013;168:75–9
   PubMed Web of Science ®Google Scholar
• Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010;203:120–6
   PubMed Web of Science ®Google Scholar
• Reid G. In vitro testing of Lactobacillus acidophilus NCFMTM as a possible probiotic for the urogenital tract. Int Dairy J 2000;10:415–19
   Web of Science ®Google Scholar
• Reid G, Zalai C, Gardiner G. Urogenital lactobacilli probiotics, reliability, and regulatory issues. J Dairy Sci 2001;84:164–9
   Google Scholar
• Uehara S, Monden K, Nomoto K, et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006;28:30–4
   PubMed Web of Science ®Google Scholar
• Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release 2005;103:301–13
   PubMed Web of Science ®Google Scholar
• Zárate G, Nader-Macias ME. Viability and biological properties of probiotic vaginal lactobacilli after lyophilization and refrigerated storage into gelatin capsules. Process Biochem 2006;41:1779–85
   Web of Science ®Google Scholar
• Pineiro M, Stanton C. Probiotic bacteria: legislative framework – requirements to evidence basis. J Nutr 2007;137:850–3
   PubMed Web of Science ®Google Scholar
• Matu MN, Orinda GO, Njagi ENM, et al. In vitro inhibitory activity of human vaginal lactobacilli against pathogenic bacteria associated with bacterial vaginosis in Kenyan women. Anaerobe 2010;16:210–15
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Matsumoto M. Pharmaceutical evaluation of hollow type suppositories. IV. Improvement of bioavailability of propranolol in rabbits after rectal administration. J Pharmacobio-Dynam 1986;9:526–31
   PubMedGoogle Scholar
• European Pharmacopeia. 7th ed. Strasbourg Council of Europe; 2013
   Google Scholar
• Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999;59:91–5
   PubMed Web of Science ®Google Scholar
• das Neves J, Amaral MH, Bahia MF. Performance of an in vitro mucoadhesion testing method for vaginal semisolids: influence of different testing conditions and instrumental parameters. Eur J Pharm Biopharm 2008;69:622–32
   PubMed Web of Science ®Google Scholar
• Li B, Zaveri T, Ziegler GR, Hayes JE. Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral Res 2013;97:280–4
   PubMed Web of Science ®Google Scholar
• Li D, Li P, Lin H, et al. A novel chlorin–PEG–folate conjugate with higher water solubility, lower cytotoxicity, better tumor targeting and photodynamic activity. J Photochem Photobiol 2013;127:28–37
   Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 2012;13:105–19
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. London: Pharmaceutical Press; 2009:517–21
   Google Scholar
• Pifferi G, Restani P. The safety of pharmaceutical excipients. Farmaco 2003;58:541–50
   PubMedGoogle Scholar
• Gali Y, Delezay O, Brouwers J, et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob Agents Chemother 2010;54:5105–14
   PubMed Web of Science ®Google Scholar
• Chiba K, Makino I, Ohuchi J, et al. Interlaboratory validation of the in vitro eye irritation tests for cosmetic ingredients (9). Evaluation of cytotoxicity test on HeLa cells. Toxicol In Vitro 1999;13:189–98
   PubMed Web of Science ®Google Scholar
• Thomas NW, Lack LJ, Woodhouse BA, et al. Formulation of Fenbufen suppositories. III. Histology of the rectal mucosa of rats following repeat dosing of Fenbufen in Witepsol H12 and PEG vehicles. Int J Pharm 1988;44:261–3
   Web of Science ®Google Scholar
• Thomas NW, Butterworth P, Gould PL. The effect of polyethylene glycol 1540 and Witepsol H12 suppositories on the store of rectal mucus in the rat. Int J Phar 1989;53:261–4
   Web of Science ®Google Scholar
• Miyake M, Kamada N, Oka Y, et al. Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine. J Control Release 2004;99:63–71
   PubMed Web of Science ®Google Scholar
• Kaewnopparat S, Kaewnopparat N. Formulation and evaluation of vaginal suppositories containing lactobacillus. WASET 2009;55:25–8
   Google Scholar
• Kaewsrichan J, Chandarajoti K, Kaewnopparat S, Kaewnopparat N. Evaluation of lactobacilli containing suppository formulation for probiotic use. Mu J Pharm 2007;34:1–8
   Google Scholar
• Hosny EA, Abdel-Hady SS, El-Tahir KEH. Formulation, in-vitro release and ex-vivo spasmolytic effects of mebeverine hydrochloride suppositories containing polycarbophil or polysorbate 80. Int J Phar 1996;142:163–8
   Web of Science ®Google Scholar
• Cavaliere Ved. Vesely RMA, De Simone C. Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections and related method. Patent US 6277370 B1, United States of America, 2001
   Google Scholar
• Uehara S, Monden K, Nomoto K, et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006;28:30–4
   PubMed Web of Science ®Google Scholar
• Garg S, Goldman D, Krumme M, et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010;88:19–29
   PubMed Web of Science ®Google Scholar
• Fazeli MR, Toliyat TS, Samadi N, et al. Viability of Lactobacillus acidophilus in various vaginal tablet formulations. DARU 2006;14:172–7
   Google Scholar
• Maggi L, Mastromarino P, Macchia S, et al. Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration. Eur J Pharm Biopharm 2000;50:389–95
   PubMed Web of Science ®Google Scholar
• Mastromarino P, Brigidi P, Macchia S, et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol 2002;93:884–93
   PubMed Web of Science ®Google Scholar
• Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: where have we been? Where are we going? J Womens Health Gend Based Med 2001;10:163–73
   PubMedGoogle Scholar
• Hardy E, de Padua KS, Osis MJ, et al. Women’s preferences for vaginal antimicrobial contraceptives. IV. Attributes of a formulation that would protect from STD/AIDS. Contraception 1998;58:251–5
   PubMed Web of Science ®Google Scholar
• Hardy E, Jimenez AL, de Padua KS, Zaneveld LJ. Women’s preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 1998;58:245–9
   PubMed Web of Science ®Google Scholar
• Bentley ME, Fullem AM, Tolley EE, et al. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 2004;94:1159–64
   PubMed Web of Science ®Google Scholar
• Rosen RK, Morrow KM, Carballo-Dieguez A, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) 2008;17:383–92
   PubMed Web of Science ®Google Scholar